4.4 Article

Antisense Oligonucleotide Therapy Targeted AgainstATXN3Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Neurosciences

Pathogenesis of SCA3 and implications for other polyglutamine diseases

Hayley S. McLoughlin et al.

NEUROBIOLOGY OF DISEASE (2020)

Article Clinical Neurology

In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3

Maria do Carmo Costa et al.

MOVEMENT DISORDERS (2020)

Review Neurosciences

Ion channel dysfunction in cerebellar ataxia

David D. Bushart et al.

NEUROSCIENCE LETTERS (2019)

Article Medicine, General & Internal

Spinocerebellar ataxia

Thomas Klockgether et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Article Clinical Neurology

Neurochemical abnormalities in premanifest and early spinocerebellar ataxias

James M. Joers et al.

ANNALS OF NEUROLOGY (2018)

Article Clinical Neurology

Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice

Hayley S. McLoughlin et al.

ANNALS OF NEUROLOGY (2018)

Article Clinical Neurology

Structural signature of SCA3: From presymptomatic to late disease stages

Thiago Junqueira Ribeiro Rezende et al.

ANNALS OF NEUROLOGY (2018)

Article Clinical Neurology

Targeting potassium channels to treat cerebellar ataxia

David D. Bushart et al.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)

Review Clinical Neurology

Spinocerebellar ataxias: prospects and challenges for therapy development

Tetsuo Ashizawa et al.

NATURE REVIEWS NEUROLOGY (2018)

Article Biochemistry & Molecular Biology

Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2

James M. Dell'Orco et al.

HUMAN MOLECULAR GENETICS (2017)

Review Neurosciences

Polyglutamine spinocerebellar ataxias - from genes to potential treatments

Henry L. Paulson et al.

NATURE REVIEWS NEUROSCIENCE (2017)

Article Medicine, Research & Experimental

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice

Lodewijk J. A. Toonen et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2017)

Article Medicine, Research & Experimental

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models

Lauren R. Moore et al.

MOLECULAR THERAPY-NUCLEIC ACIDS (2017)

Article Clinical Neurology

In Vivo Neurometabolic Profiling in Patients With Spinocerebellar Ataxia Types 1, 2, 3, and 7

Isaac M. Adanyeguh et al.

MOVEMENT DISORDERS (2015)

Article Clinical Neurology

Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes

Sophie Tezenas du Montcel et al.

Article Biology

Cerebellar modules operate at different frequencies

Haibo Zhou et al.

Article Biochemistry & Molecular Biology

Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2

Stephen T. Hansen et al.

HUMAN MOLECULAR GENETICS (2013)

Article Biochemistry & Molecular Biology

Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spioncerebellar ataxia type 1

Uzay E. Emir et al.

JOURNAL OF NEUROCHEMISTRY (2013)

Article Biotechnology & Applied Microbiology

Toward RNAi Therapy for the Polyglutamine Disease Machado-Joseph Disease

Maria do Carmo Costa et al.

MOLECULAR THERAPY (2013)

Review Clinical Neurology

Brain pathology of spinocerebellar ataxias

Kay Seidel et al.

ACTA NEUROPATHOLOGICA (2012)

Article Clinical Neurology

Mutations in Potassium Channel KCND3 Cause Spinocerebellar Ataxia Type 19

Anna Duarri et al.

ANNALS OF NEUROLOGY (2012)

Article Clinical Neurology

Mutations in KCND3 Cause Spinocerebellar Ataxia Type 22

Yi-Chung Lee et al.

ANNALS OF NEUROLOGY (2012)

Article Neurosciences

Mouse Ataxin-3 Functional Knock-Out Model

Pawel M. Switonski et al.

NEUROMOLECULAR MEDICINE (2011)

Review Clinical Neurology

Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond

Alexandra Durr

LANCET NEUROLOGY (2010)